Trial Profile
PET Occupancy study of ABX-1431 in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Elcubragistat (Primary)
- Indications Central pain; Epilepsy; Neurogenic inflammation; Neurological disorders
- Focus Pharmacodynamics
- 19 May 2016 New trial record
- 10 May 2016 According to Abide Therapeutics media release, company announced the initiation of enrollment and dosing in this study.